Development and Scale up in API Manufacture (Part 2 Quality Assurance Considerations)

Size: px
Start display at page:

Download "Development and Scale up in API Manufacture (Part 2 Quality Assurance Considerations)"

Transcription

1 Development and Scale up in API Manufacture (Part 2 Quality Assurance Considerations) Tuesday 6 th October 2009 Dr. Claire Mc Donnell, D.I.T. 1

2 Contents Regulation of API Manufacture Comparison of API and finished drug production Process Stages involved in API synthesis Generation of Impurities Case study; therapeutic grade peptide synthesis at Kinerton Ltd Technology Transfer Summary Bibliography 2

3 Regulation of API Manufacture FDA applies cgmp regulations to bulk API manufacture Mutual recognition agreement is finalised (EU, Japan and USA are the 3 ICH regions) Inspections on API manufacturers carried out using ICH Guideline Q7A GMP Guide for Active Pharmaceutical Ingredients (August 2001) ( API S regulated in EU according to Eudralex GMP guide, Annex 18 (July 2001/ (May 2004 (2004/27)). Same as ICH Q7A. ( 4/pdfs-en/v4an18.pdf ) 3

4 Comparison of API and Finished Drug Production API Manufacture Raw materials undergo some significant chemical change. Purification will be required to remove impurities, contaminants, solvents, unwanted crystalline / molecular forms etc. Purification achieved by various chemical, physical and / or biological processing steps. Effectiveness of the purification confirmed by chemical, biological and physical tests on the API 4

5 Comparison of API and Finished Drug Production cont d Finished Drug Product Production Quality of the drug ingredients and the care exercised in handling them predetermines purity of finished product. Purification steps not usually involved. 5

6 Types of API Manufacturing Process Chemical synthesis Natural product extraction Fermentation Enzymatic reactions Recombinant DNA technology 6

7 1. Reaction Process Stages Involved in API Chemical Synthesis (continuous/batch, multi-purpose/dedicated) 2. Separation (extraction/phase separation, centrifugation) 3. Purification (filtration, distillation, crystallisation, chromatography) 4. Drying (dryer, lyophiliser) 7

8 1. Reaction Reactor usually glass-lined steel with jacket and fixed agitator. - Need reactor vessel cleaning validation. Test to confirm removal of residues Usual Process Steps; Addition of raw materials and solvents. Mixing. Heating / Cooling. In-process monitoring. Carry out testing at maximum, middle and minimum of ranges quoted in SOP s 8

9 Reaction Stage - Purpose and Limitations Chemical transformation of raw materials to generate product/intermediate of specific molecular structure. Wide general application. Temperature range available usually 20 to 140 o C. Solid reagents can cause handling difficulties Effective sampling method required. Good reactor design will ensure an effective process that s in control. 9

10 2. Separation Extraction/phase separation extraction involving aqueous and organic phases separates inorganic and organic material. Some purification usually obtained. Rapid, effective phase separation required. Significant partition difference between product and impurities required. Centrifugation highly efficient and enclosed filtration system. Product then requires manual transfer to dryer however. 10

11 3. Purification Filtration used to remove residual solid impurities from a liquid or solution. Wide applications. Filter components must be appropriate to solvents / chemicals. Distillation commonly used purification /separation process for liquids. Requires b.p. difference of 15 o C and easily achievable pressure and temperature conditions. Won t separate mixture if an azetrope (constant boiling mixture) forms between starting composition and purity required. Can t separate compounds of very similar chemical structure. Sampling difficult under vacuum conditions. Energy costs can be significant. 11

12 3. Purification cont d Crystallisation common method for purification of solids. Cooling rate affects particle size. Consistent crystal morphology required from process. Requires filtration and washing; need efficient removal of mother liquor and washes. Chromatography very efficient purification. Dilute solutions necessary (large solvent volume and low throughput) specialised equipment high cost. Expensive technique on large scale. Only applicable to high value products. 12

13 4. Drying Dryer oven, vacuum, spray, fluid bed (many models / types available). Removal of residual solvent. Manual transfer often necessary exposure/degree of protection assessment. Organic vapours may be given off. Not applicable to heat-sensitive product. Lyophilisation freeze-drying. Used for heat-sensitive products. 13

14 Double drum dryer 14

15 Critical Steps in API Manufacture Design of API manufacturing plants traditionally like chemical manufacturing plants (traces of contaminants usually acceptable). Rigid controls may not be required or feasible in early processing steps. cgmp regulations apply to manufacture of drugs in their final dose form but FDA applies them to bulk API manufacture and to drug intermediate manufacture if the manufacture of the intermediate is a critical step. 15

16 Critical Steps in API Manufacture cont d Critical step affects part of the drug s characterisation (for example, its crystalline form) or impurity profile. Critical step must be controlled within predetermined criteria to ensure the API meets its specification. Step after which recovery from process malfunction or contamination is not possible. Not limited to final stage of API process. Can include intermediate steps that 1) Introduce essential molecular structure element or result in a major chemical transformation 2) Introduce significant impurities into the product 3) Remove significant impurities from the product 16

17 Critical Steps in API Manufacture cont d Therefore, a step can be critical due to its chemistry (control critical parameters) or with regard to contamination (control contamination sources such as operator procedures and environment). Critical parameter processing parameter which directly influences the drug characterisation or impurity profile of a drug in a critical step (e.g. temperature). Need to show have consistent control of critical parameters in critical processes. Instruments used to measure critical parameters require enhanced documentation (critical instruments). Reasonable acceptance criteria set between vendor claim and process requirement. 17

18 Critical Areas in Production of Product X Description Stage Process Step Agitation Rate Crystallization IV-A, C, H, J, P, Q, AE Temperature increase Hydrolysis Temperature increase Isolation III-O Temperature holding/maintaining Temperature holding/maintaining Temperature holding/maintaining Hydrolysis Crystallization Drying V-E Temperature Cooling Crystallization III-R, III-T ph Hydrolysis ph Crystallization IV-R, T, C, H, J, E, N, Q, R, S, V 18

19 Example of Manufacturing Scale Process Extract from Batch Log Sheet for Crystallisation 1.Adjust temperature to o C 2.While maintaining the temperature at o C, add 10% of the total charge of sulphuric acid. Note The sulphuric acid should be charged subsurface 3.Seed the mixture with 0.2 5% of Product X 4. Agitate the mixture at o C for 30 minutes. 5. Add the remaining sulphuric acid over 2 to 3 hours while keeping the temperature at o C 19

20 Regulatory Requirements At validation stage (3 batches), all parameters should be fixed and development complete (beyond experimental stage) DESIGN quality in, can t test it in. Post approval changes necessary due to continuous improvement requirement and changes in circumstances (raw material vendors, vegetable extracts instead of animal (BSE) etc.). 20

21 Post-Approval Changes SUPAC (scale up post approval changes) BACPAC (bulk actives post approval changes) CBE (changes being effected) Reporting categories - Major change (Prior Approval Supplement) - Moderate change (Supplement Changes Being Effected in 30 days or Supplement Changes Being Effected) - Minor change (next Annual Report) 21

22 Post Approval Changes Criteria used are potential for change to have effect on identity, strength, quality, purity or potency of the drug product. FDA Guidance Document Changes to an Approved NDA or ANDA, Nov 1999 ( FDA Guidance Document BACPAC I : Intermediates in Drug Substance Synthesis, Feb 2001 ( 22

23 Generation of Impurities Impurities - chemical (moisture, solvent, side-products), biological (endotoxin & microbial levels) and physical (particle size, homogeneity, specific bulk density outside specifications). Before defining critical steps in API manufacture, need to characterise the final drug substance including its impurity profile. (Identify impurities at > 0.1%) Impurity profile provides fingerprint for acceptance of each API batch. Recommended to submit relatively impure batch for safety/toxicology studies i.e. acceptance criteria that can readily be met and allow acceptable product quality. 23

24 Case Study; Therapeutic Grade Peptide Synthesis at Kinerton Ltd. Process Steps for A Specialised API Manufacturing Process BACKGROUND Ipsen Ltd produces synthetic peptides (10-12 amino acid sequences) which are API S. Applications cancer, diabetes, growth disorders Annual production ~ 20 Kg. Potent, high value API. Therapeutic delivery of peptides difficult due to short half-life (< 1 hour) and susceptibility to enzymatic degradation. Currently Ipsen s API is finished in sustained release formulation by a sister company in France. 24

25 Case Study; Therapeutic Grade Peptide Synthesis at Kinerton Ltd. Production of API separated into synthesis followed by purification and drying processes. SYNTHESIS Solid Phase Peptide Synthesis - Classical method (Merrifield, 1960 s) - Amino acids (a.a. s) can be assembled into a peptide of any desired sequence while one end of the a.a. chain is anchored to an insoluble support (resin). - 1 st a.a. attached to resin via linker, it s amino protecting group is removed and 2 nd a.a. is added. Amino protecting group of 2 nd a.a. removed and 3 rd a.a. added, etc - After desired sequence of a.a. s joined together on the support, cleave chain from support and finished peptide is liberated into solution. 25

26 Case Study; Therapeutic Grade Peptide Synthesis at Kinerton Ltd. - Critical requirement that carry out in process testing to ensure complete deprotection and then coupling (Kaiser-Ninhydrin test). - No isolation of intermediates. - Reactors used 50L glass with sintered glass frit at base. - Product dedicated, batch production. After cleavage, crude product extracted and precipitated. Then solubilised in dilute acetic acid. Tested to determine crude purity (50 70%) and yield. 26

27 Case Study; Therapeutic Grade Peptide Synthesis at Kinerton Ltd. PURIFICATION Preparative Scale HPLC - Very powerful technique, high reproducibility. - Expensive, high dilutions. - Chromatography distribution phenomenon between stationary (silica packing) and mobile phase (buffer/solvent system). All compounds spend same time in mobile phase but different times in stationary phase. - Purified product of > 99% (no impurities > 0.5%) obtained as solution in acetic acid buffer. NOTE - Potential of SMB (Simulated Moving Bed) Chromatography instead of Prep HPLC. 27

28 Prep Scale HPLC Systems 28

29 Case Study; Therapeutic Grade Peptide Synthesis at Kinerton Ltd. DRYING Lyophilisation - Solution of purified peptide freeze-dried to produce dry solid cake. - Critical parameters cycle used (temperatures, times, pressure), concentration of peptide solution affect drying and physical characteristics of product (e.g. SSA). -Exposure vertical laminar flow cleanroom (class 100) used for lyophilisation and packaging to protect API product. 29

30 Technology Transfer Overlap with Development and Scale up. Several pharmaceutical firms recently used SUPAC guidelines to move products that were former blockbuster drugs to contract manufacturers and renovated their vacated manufacturing sites for new blockbusters Subtle differences in processing equipment most overlooked area causing delays and failures in technology transfer (e.g. define pumping and spraying systems, mixer / homogeniser types, filter type and porosity for fluid bed) 30

31 Technology Transfer cont d Analytical methods transfer very important define equipment set-up and settings, calibration schedules, weighing and injection techniques and sample preparation methods (visits to new site) Equivalence of data between sites must be assured economic, compliance and regulatory aspects Stability programme requires consideration 31

32 Technology Transfer - Factors for Success Communication often difficult to achieve. Timely (mechanism?), Clear - nothing left to interpretation, Oral communications documented, All critical departments included. Quality Compliance with regulations, continuous evaluation, corporate culture Timeliness - Expectations clarified, critical milestones clearly identified Relationship - Cooperation and partnership approach, visits and meetings Robust process slight changes in operating parameters should give comparable results 32

33 Summary Are a series of usual process stages and a range of equipment usually employed in API manufacture Important to identify critical steps and parameters in process as soon as possible Specialised techniques and equipment may be employed if process will still be cost effective Post approval changes type of change determines reporting category Technology transfer communication and analytical data equivalence vital 33

34 Bibliography Change Control in the Pharmaceutical Industry, Lecture, Patricia Sheehan, Leo Labs, Nov ICH Guideline Q7A GMP Guidance for Active Pharmaceutical Ingredients, August 2001 ( Chemical Development and Scale-Up in the Fine Chemical Industry, Course Notes from Trevor Laird, Scientific Update, Scale Up and Transfer with Manufacturing, Michael J. Valazza, Contract Pharma, Dec ( 34

35 FURTHER READING: Bibliography cont d Organic Process Research and Development, Journal (Amer Chem Soc / RSC). In DIT Kevin St. Pharmaceutical Technology Europe, Journal (Advanstar Publishing) - Accessible electronically on DIT library catalogue or subscribe to for free at 35

36 RSC Library and Information Centre 36

Cleaning and Cleaning Validation of API Plant and Equipment

Cleaning and Cleaning Validation of API Plant and Equipment Regulatory Basis: FDA Quality Systems Regulations Reference: FDA CFR - Code of Federal Regulations Title 21 1 Purpose The purpose of this guideline is: To define the requirements for cleaning plant and

More information

Elemental impurities impact on APIs

Elemental impurities impact on APIs Regulatory Expectations on impurities in Drug Substances: Authority and Industry perspective Pavia, 2nd October 2015 Elemental impurities impact on APIs October 2 nd 2015 Annalisa Scali RegulatoryAffairsManager

More information

Switzerland EXPERTS TAKING CARE

Switzerland EXPERTS TAKING CARE CordenPharma Switzerland EXPERTS TAKING CARE CordenPharma Switzerland Eichenweg 1 4410 Liestal Switzerland Phone +41 61 906 59 59 Fax +41 61 906 59 58 sales@cordenpharma.com www.cordenpharma.com Our History

More information

Regulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.

Regulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd. Regulatory Aspects of Cleaning and Cleaning Validation Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd. 28 June 2017 Why clean? Pharmaceutical production equipment is cleaned

More information

Validation of Pharmaceutical Manufacturing Process Focus: APIs.

Validation of Pharmaceutical Manufacturing Process Focus: APIs. Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised

More information

Guideline for Descriptions on Application Forms for Marketing Approval of Drugs, etc. under the Revised Pharmaceutical Affairs Law

Guideline for Descriptions on Application Forms for Marketing Approval of Drugs, etc. under the Revised Pharmaceutical Affairs Law Tentative translation (as of March 16, 2007) *This is the revised version as based on the PFSB/ELD Notification No. 0112001 issued by the Director of Evaluation and Licensing Division, Pharmaceutical and

More information

E24 PURIFICATION OF ORGANIC COMPOUNDS Distillation, recrystallisation, melting and boiling point determination

E24 PURIFICATION OF ORGANIC COMPOUNDS Distillation, recrystallisation, melting and boiling point determination E24 PURIFICATION OF ORGANIC COMPOUNDS Distillation, recrystallisation, melting and boiling point determination THE TASK To learn the main techniques of purifying organic compounds. THE SKILLS By the end

More information

Health Products and Food Branch Inspectorate Graham Spry Building, 3 rd Floor 250 Lanark Avenue Address Locator # 2003D OTTAWA, Ontario K1A 0K9 January 4, 2008 07-128997-672 TO: ALL INTERESTED PARTIES

More information

EXPERTISE BIOMASS PRETREATMENT

EXPERTISE BIOMASS PRETREATMENT EXPERTISE BIOMASS PRETREATMENT BIOMASS PRETREATMENT PRODUCT RECOVERY AND PURIFICATION BIOMASS PRETREATMENT Equipment overview: Reactors for chemical pretreatment of biomass: These reactors are suitable

More information

Inspection. Implementation of ICH Q8, Q9, Q10

Inspection. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory

More information

Conducting Supplier Audits: Ensure Validation Compliance

Conducting Supplier Audits: Ensure Validation Compliance Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why

More information

Module: 7. Lecture: 37

Module: 7. Lecture: 37 Module: 7 Lecture: 37 DIMETHYL SULFOXIDE INTRODUCTION Dimethyl sulfoxide, denoted as O, is an organosulfur compound with having the formula (CH3)2SO. It is a colourless liquid and an important polar aprotic

More information

Developing Pharmaceutical Continuous Crystallization Processes - Knowledge & Gaps. Chris Price on behalf of the IMI team Product Development

Developing Pharmaceutical Continuous Crystallization Processes - Knowledge & Gaps. Chris Price on behalf of the IMI team Product Development Developing Pharmaceutical Continuous Crystallization Processes - Knowledge & Gaps Chris Price on behalf of the IMI team Product Development Context - Innovative Manufacturing Initiative Move from Batch,

More information

Cleaning Procedures. These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products

Cleaning Procedures. These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products CLEANING DEVELOPMENT Cleaning Procedures as the FDA See It These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products BPC CLEANING (& Drug Products)

More information

EXPERTISE BIOMASS PRETREATMENT BIOMASS PRETREATMENT BIOCATALYSIS FERMENTATION GREEN CHEMISTRY PRODUCT RECOVERY AND PURIFICATION

EXPERTISE BIOMASS PRETREATMENT BIOMASS PRETREATMENT BIOCATALYSIS FERMENTATION GREEN CHEMISTRY PRODUCT RECOVERY AND PURIFICATION BIOMASS PRETREATMENT BIOMASS PRETREATMENT BIOCATALYSIS FERMENTATION GREEN CHEMISTRY PRODUCT RECOVERY AND PURIFICATION BIOMASS PRETREATMENT Equipment overview: Reactors for chemical pretreatment of biomass:

More information

The Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager

The Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define

More information

Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission

Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission 1 2 3 25 April 2014 EMA/CHMP/BWP/187338/2014 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on process validation for the manufacture of biotechnology-derived active substances

More information

White Paper. Crystallization in Process Chemistry Applying Simple PAT Tools. Author: Des O'Grady PhD, METTLER TOLEDO

White Paper. Crystallization in Process Chemistry Applying Simple PAT Tools. Author: Des O'Grady PhD, METTLER TOLEDO Crystallization in Process Chemistry Applying Simple PAT Tools Author: Des O'Grady PhD, Crystallization is a common step used during the synthesis of organic compounds to isolate and purify the desired

More information

Current version 13 October 2016

Current version 13 October 2016 Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order

More information

Journal of Atoms and Molecules

Journal of Atoms and Molecules Review article Journal of Atoms and Molecules An International Online Journal ISSN 2277 1247 CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRIES Abhishek Raj Senior R&D Officer, Quest Pharmaceuticals Pvt.

More information

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)

More information

Adopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016

Adopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016 1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological

More information

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any

More information

BRUSSELS CORDENPHARMA EXPERTS TAKING CARE

BRUSSELS CORDENPHARMA EXPERTS TAKING CARE CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Corden Pharma Brussels S.A. 310 rue de Ransbeek 1120 Brussels Belgium Phone +32 2 263 1411 www.cordenpharma.com/contact-us/ www.cordenpharma.com Our History 1987:

More information

CORDENPHARMA BRUSSELS EXPERTS TAKING CARE

CORDENPHARMA BRUSSELS EXPERTS TAKING CARE CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Our History 1987: Peptisyntha founded by Solvay 1996: First pre-approval FDA inspection for a major peptide made by Peptisyntha for the worldwide market. Following

More information

Analytical and formulation attributes

Analytical and formulation attributes Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding

More information

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs

More information

Overview of Regulatory Requirements for API and Formulations

Overview of Regulatory Requirements for API and Formulations Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed

More information

Q & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011

Q & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011 1. For day of use calibration, why does the chapter recommend only 2 injections of the known standard versus current standard of 3? Response: The current Chapter does not specify a number of standard

More information

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not

More information

CGMP Requirements for Investigational Products

CGMP Requirements for Investigational Products PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health

More information

Supplement to the September 2010 Issue. CPhI/ICSE Supplement: API Synthesis, Formulation Development, and Manufacturing

Supplement to the September 2010 Issue. CPhI/ICSE Supplement: API Synthesis, Formulation Development, and Manufacturing 2010 Supplement to the September 2010 Issue CPhI/ICSE Supplement: API Synthesis, Formulation Development, and Manufacturing Continuous chromatography Evolution of Continuous Chromatography: Moving Beyond

More information

How do you know the drug you are using is safe and effective?

How do you know the drug you are using is safe and effective? The Chemistry, Manufacturing, and Controls (CMC) Technical Section: The Big Picture of a Long-term Commitment AAVPT Workshop February 28, 2011 James K. Nitao, Ph.D. Biotherapeutics Team Division of Manufacturing

More information

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood

More information

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016 EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials

More information

RE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use

RE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 14 March 2008 European Commission Enterprise and Industry Directorate-General B-1049 Brussels Belgium BY EMAIL TO entr-gmp@ec.ec.europa.eu

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco

More information

While the recognition

While the recognition Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change

More information

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

USP Chapter 823 USP 32 (old) vs. USP 35 (new) USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has

More information

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls

More information

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference

More information

H N 2. Decolorizing carbon O. O Acetanilide

H N 2. Decolorizing carbon O. O Acetanilide Experiment 1: Recrystallization of Acetanilide Reading Assignment Mohrig 2 4 (Glassware, Reagents, & Heating) & 14 15 (Melting Point & Recrystallization) The purification of organic compounds is a tedious,

More information

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Guidelines for Process Validation of Pharmaceutical Dosage Forms Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical

More information

QA Production Material and Analytical Methods. BIT 230 Chapters 5 and 6 (Huxsoll)

QA Production Material and Analytical Methods. BIT 230 Chapters 5 and 6 (Huxsoll) QA Production Material and Analytical Methods BIT 230 Chapters 5 and 6 (Huxsoll) Material Selection Original qualification of material - vendor, specifications, safety, function, etc. Lot-to-lot testing

More information

Inspection Trends. American Society for Quality Richmond, VA Section March 8, 2016

Inspection Trends. American Society for Quality Richmond, VA Section March 8, 2016 Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality

More information

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical

More information

Assistant Lecturer. Sahar Mohammed Shakir Assistant Lecturer. Abdul Hafeedh Hameed Assistant Lecturer. Ali Basim

Assistant Lecturer. Sahar Mohammed Shakir Assistant Lecturer. Abdul Hafeedh Hameed Assistant Lecturer. Ali Basim Assistant Lecturer Sahar Mohammed Shakir Assistant Lecturer Abdul Hafeedh Hameed Assistant Lecturer Ali Basim Solid organic cpd.s when isolated from organic reaction are impure; they are contaminated with

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

VICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES

VICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN

More information

The place of the Certification Procedure in the global regulatory environment

The place of the Certification Procedure in the global regulatory environment The place of the Certification Procedure in the global regulatory environment 19-20/09/2017 - Prague Workshop 1: how to build up a good CEP application Top ten deficiencies Cristian SAMPAOLESI Reference

More information

ABB Industries PAT Validation

ABB Industries PAT Validation Alison Harrington ABB Industries PAT Validation ABB Industries - 1 - Topics PAT disciplines and framework FDA evolution PAT Regulatory Process Quality System Comparability Protocol Submission example Validation

More information

Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols

Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols Joint BWP/QWP/GMDP IWG Industry European Workshop on Lifecycle Management Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols 1 Outline Introduction: evolution of PACMP

More information

Draft agreed by Quality Working Party 7 June Adopted by CHMP for release for consultation 28 June 2018

Draft agreed by Quality Working Party 7 June Adopted by CHMP for release for consultation 28 June 2018 1 13 November 2018 2 EMA/CHMP/CVMP/QWP/496873/2018 3 4 Committee for Medicinal Products for Human Use (CHMP) 5 Committee for Medicinal Products for Veterinary Use (CVMP) 6 7 8 Draft Draft agreed by Quality

More information

Microbiological Cleaning Method Validation

Microbiological Cleaning Method Validation Microbiological Cleaning Method Validation The purpose of cleaning procedures should never be to reduce bioburden to an acceptable level! Fergus O Connell QA Manager Eurofins ams Laboratories www.eurofins.com

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances

ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE

More information

Dynamic Axial compression Liquid Chromatography Columns. Flash MPLC HPLC UHPLC. Proven, scalable technology for classic purification techniques

Dynamic Axial compression Liquid Chromatography Columns. Flash MPLC HPLC UHPLC. Proven, scalable technology for classic purification techniques Dynamic Axial compression Liquid Chromatography Columns Flash MPLC HPLC UHPLC Proven, scalable technology for classic purification techniques Synthesis Purification Expand the Boundaries of Liquid Chromatography

More information

Amazon FILTRATION SOLUTIONS PHARMACEUTICAL MANUFACTURING

Amazon FILTRATION SOLUTIONS PHARMACEUTICAL MANUFACTURING Amazon FILTRATION SOLUTIONS PHARMACEUTICAL MANUFACTURING FILTRATION SOLUTIONS FOR PHARMACEUTICAL MANUFACTURING Delivering quality filtration products As one of Europe s leading manufacturers of process

More information

Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances

Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances 3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for

More information

Design and Implementation of a Small Footprint Continuous API facility for Portfolio Commercialization. Eoin McManus Eli Lilly and Company March 2016

Design and Implementation of a Small Footprint Continuous API facility for Portfolio Commercialization. Eoin McManus Eli Lilly and Company March 2016 Design and Implementation of a Small Footprint Continuous API facility for Portfolio Commercialization Eoin McManus Eli Lilly and Company March 2016 Agenda 1. Drivers for Continuous API 2. Phase 1: Platform

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015 Ref. Ares(2015)3808922-15/09/2015 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, [date] This document is for consultation until 11

More information

Chapter No. 2 EXPERIMENTAL TECHNIQUES IN CHEMISTRY LONG QUESTIONS Analytical Chemistry: The science of chemical characterization is called analytical chemistry. OR The branch of chemistry which deals with

More information

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit. FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis

More information

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities) May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological

More information

Company Overview and Products & Services

Company Overview and Products & Services Company verview and Products & Services amari Chemicals - Content 1. amari Chemicals: Company verview 2. ur Products & Services Peptides R&D Services Manufacturing Services Corporate istory 1948 amari

More information

Systems-Based Inspections for Cleaning Validation

Systems-Based Inspections for Cleaning Validation Systems-Based Inspections for Cleaning Validation FDA DG 230 July 27, 2015 Rockville, MD Destin A. LeBlanc Cleaning Validation Technologies www.cleaningvalidation.com 1 Objectives Describe and/or identify:

More information

Change Control Overview

Change Control Overview Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change

More information

Strategies for IND Filing Success: Chemistry, Manufacturing and Controls

Strategies for IND Filing Success: Chemistry, Manufacturing and Controls Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary

More information

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended

More information

HISTORY AND MILESTONES

HISTORY AND MILESTONES HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing

More information

Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective

Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh

More information

Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes

Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes Susan Dana Jones, Ph.D. BioProcess Technology Consultants BIO Process Zone Theater June 19, 2008 Microbial Process Development

More information

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API) Title: Good Working Practice Validation Requirements Practice Number: 06 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Topics: 1. Biological Test Methods

More information

Human Microbiota: proof of concept to production. Michael van der Horst Process Engineer Technical Operations SynCo Bio Partners B.V.

Human Microbiota: proof of concept to production. Michael van der Horst Process Engineer Technical Operations SynCo Bio Partners B.V. Human Microbiota: proof of concept to production Michael van der Horst Process Engineer Technical Operations SynCo Bio Partners B.V. SynCo Bio Partners B.V. Who we are and what we do Licensed cgmp CMO

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels

More information

Analysis of Protein Biopharmaceuticals

Analysis of Protein Biopharmaceuticals Analysis of Protein Biopharmaceuticals Comprehensive cgmp Services at Every Stage of Drug Development Amazing where you can go At Solvias, we work closely with you Solvias provides comprehensive services

More information

Manual: 038. Cleaning and Cleaning Validation of API Plant and Equipment

Manual: 038. Cleaning and Cleaning Validation of API Plant and Equipment Title: Cleaning and Cleaning Validation of API Plant and Equipment Manual Number: 38 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Manual: 38 Cleaning and

More information

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)

More information

CH241 Experiment #1 (Weeks of September 11, 18, and 25, 2017)

CH241 Experiment #1 (Weeks of September 11, 18, and 25, 2017) CH241 Experiment #1 (Weeks of September 11, 18, and 25, 2017) SEPARATION AND RECOVERY OF ORGANIC COMPOUNDS, THIN LAYER CHROMATOGRAPHY, COLUMN CHROMATOGRAPHY, CRYSTALLIZATION, AND MELTING POINTS Overview

More information

Research towards automated continuous flow peptide synthesis

Research towards automated continuous flow peptide synthesis Research towards automated continuous flow peptide synthesis Achema 2018 Dr Ryan Skilton MRSC Research Scientist, Vapourtec Ltd Ryan.Skilton@Vapourtec.com Why peptides? Peptides play a crucial role in

More information

Registered Starting Material Auditing Guide

Registered Starting Material Auditing Guide Registered Starting Material Auditing Guide Annex 1 Aide Mémoire Company : Auditor(s) : Location, Country : Date of Audit: APIC Guide for Auditing Registered Starting Material Manufacturers Remark: Non-compliance

More information

SynCo Bio Partners B.V. & Wacker Biotech GmbH: THE MICROBIAL CMO

SynCo Bio Partners B.V. & Wacker Biotech GmbH: THE MICROBIAL CMO CREATING TOMORROW`S SOLUTIONS SynCo Bio Partners B.V. & Wacker Biotech GmbH: THE MICROBIAL CMO Human Microbiota: Proof of Concept to Production Işil Tüzün Weber Process Engineer Technical Operations Title

More information

Recent Opportunities & Challenges in microbial manufacturing

Recent Opportunities & Challenges in microbial manufacturing Recent Opportunities & Challenges in microbial manufacturing Elise Mous, CPhI Frankfurt, Oct 24 2017 Industry trend & challenge Customer perspective on outsourcing Key trend: Overall outsourcing growth

More information

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Brand Name : BOTO GENIE 1. Introduction : BOTO GENIE (Botulinum Toxin Type A for Injection Ph.Eur)

More information

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Quality of raw materials and manufacturing of advanced therapies Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Evolution of the compendia 1820: a single recipe book 2018: Procedures and acceptance

More information

Preparative Protein Chemistry

Preparative Protein Chemistry Biochemistry 412 Preparative Protein Chemistry 19 February 2008 The Three Eras of Protein Purification 1. The Classical (Pre-Recombinant DNA) Era (pre-1978) - Proteins purified from natural sources only

More information

Traditional Validation - Downstream

Traditional Validation - Downstream EMA Expert Workshop on Validation of Manufacturing for Biological Medicinal Products Tuesday 9 th April 2013 Traditional Validation - Downstream Norbert Hentschel Content of the Presentation 5. Should

More information

Formulation Development & CTM Manufacturing Services

Formulation Development & CTM Manufacturing Services Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range

More information

Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful

Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and

More information

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT API Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Part 1: General information Name of Manufacture Unit number

More information

Essential Product and Process Parameters in Summary

Essential Product and Process Parameters in Summary CHAPTER 3 Essential Product and Process Parameters in Summary 3.1 General Considerations During the process development stage, a number of variables need to be considered; they include formulation details,

More information

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996

More information

How to build a good CEP application - ICH Q3D

How to build a good CEP application - ICH Q3D How to build a good CEP application - ICH Q3D Lisa Moore B.Sc. (Pharm), MPSI Pharmaceutical Assessor, HPRA, Ireland External Expert CEP assessor. The place of the Certification Procedure in the global

More information

Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper

Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Varian, Inc. 2700 Mitchell Drive Walnut Creek, California 94598, USA www.varianinc.com Introduction Chromatographic

More information

Detection and Quantitation of Residual Host Cell DNA

Detection and Quantitation of Residual Host Cell DNA Detection and Quantitation of Residual Host Cell DNA White Paper Author: Phil Kuhlman, Biopharmaceutical Technical Specialist 1 Abstract All biological drug products are required to be characterised for

More information

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES 1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst

More information

GLOBAL SUPPORT FOR A QUALITY SOLUTION

GLOBAL SUPPORT FOR A QUALITY SOLUTION GLOBAL SUPPORT FOR A QUALITY SOLUTION THE ULTIMATE PEPTIDE PARTNER Dear Customer, Thank you for your continued support and for the confidence you have placed in the PolyPeptide Group. Our goal is to be

More information

Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis

Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Pharma&Biotech Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Lonza Guangzhou Nansha Ltd «Twenty-five years ago Lonza built one of the world s most advanced cgmp chemical manufacturing

More information